Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,360Price:$3.47
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Chang David DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-53,393Price:$4.33
-
Jan 30, 2024 (filed on Mar 06, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:190Price:$3.60
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:341,515Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:96,600Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Douglas Earl MartinOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:147,778Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Douglas Earl MartinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:41,800Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:103,939Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:29,400Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Belldegrun ArieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:749,398Price:--
Filings by filing date
-
Apr 22, 2024 (filed on Apr 24, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,360Price:$3.47
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Chang David DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-53,393Price:$4.33
-
Jan 30, 2024 (filed on Mar 06, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:190Price:$3.60
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:341,515Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Moore Timothy L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:96,600Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Douglas Earl MartinOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:147,778Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Douglas Earl MartinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:41,800Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:103,939Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Parker Geoffrey M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:29,400Price:--
-
Jan 25, 2024 (filed on Jan 31, 2024)Insider Name:Belldegrun ArieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:749,398Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 210 East Grand Avenue SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://allogene.com |
IR: | See website |
Key People | ||
Arie S. Belldegrun Executive Chairman of the Board | David Chang President, Chief Executive Officer, Co-Founder, Director | Geoffrey M. Parker Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer |
Timothy L. Moore Executive Vice President, Chief Technical Officer | Zachary Roberts Executive Vice President - Research and Development, Chief Medical Officer | Earl Martin Douglas General Counsel |
Business Overview |
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647. |
Financial Overview |
For the fiscal year ended 31 December 2023, Allogene Therapeutics Inc revenues decreased 39% to $95K. Net loss decreased 4% to $327.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Personnel decrease of 13% to $112.5M (expense), Interest and other income, net increase from $4.6M to $18.3M (income). |
Employees: | 232 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $38.72M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.10M as of Dec 31, 2023 |
EBITDA (TTM): | -$300.29M as of Dec 31, 2023 |
Net annual income (TTM): | -$327.27M as of Dec 31, 2023 |
Free cash flow (TTM): | -$239.25M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 170,723,100 as of Apr 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |